Journal article
Sofosbuvir and velpatasvir for HCV Genotype 2 and 3 infection
GR Foster, N Afdhal, SK Roberts, N Br, EJ Gane, S Pianko, E Lawitz, A Thompson, ML Shiffman, C Cooper, WJ Towner, B Conway, P Ruane, M Bourlie, T Asselah, T Berg, S Zeuzem, W Rosenberg, K Agarwal, CAM Stedman Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2015
Abstract
BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis. In one trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or ..
View full abstractGrants
Funding Acknowledgements
Funded by Gilead Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, NCT02201953.